The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 **FORM D**

OMB APPROVAL

OMB Number: 3235-0076
Estimated average burden
hours per response: 4.00

Notice of Exempt Offering of Securities

1. Issuer's Identity			
	Previous	□	
CIK (Filer ID Number)	Names	None	Entity Type
0000882291	BISHOP EQUIT	TIES INC	X Corporation
Name of Issuer			Limited Partnership
AETHLON MEDICAL INC			Limited Liability Company
Jurisdiction of Incorporation/Organiz	zation		General Partnership
NEVADA			Business Trust
Year of Incorporation/Organization			
X Over Five Years Ago			Other (Specify)
Within Last Five Years (Specify	Year)		
Yet to Be Formed	,		
2. Principal Place of Business and	d Contact Information		
Name of Issuer			
AETHLON MEDICAL INC		Ctroot Addrson O	
Street Address 1	OLUTE 202	Street Address 2	
11555 SORRENTO VALLEY ROAD,		Suite 203	Dhara Namhara (Ianan
City	State/Province/Country	ZIP/PostalCode	Phone Number of Issuer
SAN DIEGO	CALIFORNIA	92121	619-941-0360
3. Related Persons			
Last Name	First Name		Middle Name
Frakes	James		B.
Street Address 1	Street Address 2		
11555 Sorrento Valley Road	Suite 203		
City	State/Province/Coun	try	ZIP/PostalCode
San Diego	CALIFORNIA		92121
Relationship: X Executive Officer	X Director Promoter		
Clarification of Response (if Necess	ary):		
Last Name	First Name		Middle Name
Broenniman	Edward		G.
Street Address 1	Street Address 2		.
11555 Sorrento Valley Road	Suite 203		
City	State/Province/Coun	trv	ZIP/PostalCode
San Diego	CALIFORNIA	u y	92121
Relationship: Executive Officer	_		72.21
Clarification of Response (if Necess			
Last Name	First Name		Middle News
Last Name Rossetti	First Name Angela		Middle Name
Street Address 1	Street Address 2		
	Suite 203		
11555 Sorrento Valley Road	State/Province/Coun	trv	ZIP/PostalCode
City San Diego	CALIFORNIA	u y	92121
Relationship: Executive Officer			74141
Clarification of Response (if Necess			
Last Name	First Name		Middle Name

Shah, M.D.	Chetan	S.	
Street Address 1	Street Address 2		
11555 Sorrento Valley Road	Suite 203		
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92121	
_		92121	
Relationship: Executive Officer Director	Promoter		
Clarification of Response (if Necessary):			
Last Name	First Name	Middle Name	
Gikakis	Nicolas		
Street Address 1	Street Address 2		
11555 Sorrento Valley Road	Suite 203		
City	State/Province/Country	ZIP/PostalCode	
San Diego	CALIFORNIA	92121	
Relationship: Executive Officer X Director	Promoter		
Clarification of Response (if Necessary):	_		
4. Industry Group			
Agriculture	Health Care	Retailing	
Banking & Financial Services	X Biotechnology	Restaurants	
Commercial Banking	Health Insurance	Technology	
Insurance			
Investing	Hospitals & Physicians	Computers	
Investment Banking	Pharmaceuticals	Telecommunications	
Pooled Investment Fund	Other Health Care	Other Technology	
	¬ 🗀	Other Technology	
Is the issuer registered as an investment company under	Manufacturing	Travel	
the Investment Company	Real Estate	Airlines & Airports	
Act of 1940?	Commercial	Lodging & Conventions	
Yes No	Construction		
Other Banking & Financial Services		Tourism & Travel Services	
	REITS & Finance	Other Travel	
Business Services	Residential		
Energy		Other	
Coal Mining	Other Real Estate		
Electric Utilities			
Energy Conservation			
Environmental Services			
Oil & Gas			
Other Energy			
Culci Elicigy			
5. Issuer Size			
Revenue Range OR	Annrenate Net As	sset Value Range	
X No Revenues		Net Asset Value	
	=		
\$1 - \$1,000,000	\$1 - \$5,000,00		
\$1,000,001 - \$5,000,000	\$5,000,001 - \$		
\$5,000,001 - \$25,000,000	\$25,000,001 -	\$50,000,000	
\$25,000,001 - \$100,000,000	\$50,000,001 -	- \$100,000,000	
Over \$100,000,000	Over \$100,00	0,000	
Decline to Disclose	Decline to Dis		
Not Applicable	Not Applicable		
6. Federal Exemption(s) and Exclusion(s) C	aimed (select all that apply)	!	
Rule 504(b)(1) (not (i), (ii) or (iii))	Investment	t Company Act Section 3(c)	
Rule 504 (b)(1)(i)	=	<u> </u>	
Rule 504 (b)(1)(ii)	Section 3(d	<u> </u>	
Rule 504 (b)(1)(iii)	Section 3(d	c)(2) Section 3(c)(10)	

X Rule 506(b)	Section 3(c)(3)	ion 3(c)(11)	
Rule 506(c)	Section 3(c)(4) Sect	ion 3(c)(12)	
Securities Act Section 4(a)(5)		ion 3(c)(13)	
		ion 3(c)(14)	
		011 3(0)(14)	
	Section 3(c)(7)		
7. Type of Filing			
X New Notice Date of First Sale 2025-12-08 First Sale Namendment	et to Occur		
8. Duration of Offering			
Does the Issuer intend this offering to last more than one year	r? Yes X No		
9. Type(s) of Securities Offered (select all that apply)			
X Equity	Pooled Investmer	nt Fund Interests	
Debt	Tenant-in-Commo	on Securities	
X Option, Warrant or Other Right to Acquire Another Securit	Mineral Property	Securities	
Security to be Acquired Upon Exercise of Option, Warrant Acquire Security	or Other Right to Other (describe)		
10. Business Combination Transaction			
Is this offering being made in connection with a business comor exchange offer?	bination transaction, such as a merger, a	cquisition Yes X No	
Clarification of Response (if Necessary):			
11. Minimum Investment			
Minimum investment accepted from any outside investor $\$0\ \mbox{U}$	JSD		
12. Sales Compensation			
Recipient	Recipient CRD Number X	None	
N/A	None		
(Associated) Broker or Dealer None	(Associated) Broker or Deal	er CRD Number None	
Maxim Group, LLC	120708		
Street Address 1	Street Address 2		
300 Park Avenue	16th Floor		710/0 / / 0 /
City New York	State/Province/Country NEW YORK		ZIP/Postal Code 10022
State(s) of Solicitation (select all that apply)			10022
Check "All States" or check individual States	Foreign/non-US		
NEW YORK			
13. Offering and Sales Amounts			
To. One mig and Gales Amounts			
Total Offering Amount \$2,153,700 USD or Indefinite			
Total Amount Sold \$2,153,700 USD			
Total Remaining to be Sold \$0 USD or Indefinite			
Clarification of Response (if Necessary):			
14. Investors			
Select if securities in the offering have been or may be so	old to persons who do not qualify as accre	edited investors, and enter the number o	.f
such non-accredited investors who already have invested Regardless of whether securities in the offering have bee total number of investors who already have invested in the	I in the offering. n or may be sold to persons who do not q		
15. Sales Commissions & Finder's Fees Expenses			

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$214,500 USD X Estimate	
Finders' Fees \$0 USD Estimate	
Clarification of Response (if Necessary):	
Maxim Group, LLC has the option to subscribe for and purchase up to 96,059 shares of Common Stock.	
16. Use of Proceeds	
Maxim Group, LLC has the option to subscribe for and purchase up to 96,059 shares of Common Stock.	
\$0 USD Estimate	
Clarification of Response (if Necessary):	

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

Signature and Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.
- · Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
AETHLON MEDICAL INC	James B. Frakes	James B. Frakes	Chief Executive Officer	2025-12-23

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.